U.K. developer Quell Therapeutics hired eXmoor Pharma to make supplies of its pipeline of novel immunosuppressive cell therapies—called CAR-Tregs—at its new cell and gene therapy facility.
Quell recently teamed with fellow U.K.-based eXmoor in a “strategic partnership” that will see the contractor make its candidate autoimmune disease cell therapies for early-phase clinical studies. Quell’s pipeline consists of cell therapies derived from CAR-Tregs, a subset of T lymphocyte cells that act to maintain immune tolerance by suppressing unwanted immune responses. CAR-Tregs differ markedly from CAR-T therapies in terms of both their therapeutic function and how they are manufactured, according to Quell CBO, Luke Henry.
“Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to specific tissues via CAR engineering, to focus the suppressive activity of the CAR-Treg cells at the site of disease,” he said. “This could be applicable across multiple disease areas where there is immune dysregulation, including transplantation, autoimmunity, and inflammation.
Different strategy
“This strategy is different from traditional CAR-T products, which use the other major subset of T cells—the cytotoxic T effector cells—to induce the elimination of cancer cells.
This was echoed by Lucy Foley, PhD, CTO, at eXmoor, who said “Manufacturing CAR-Tregs requires a unique, proprietary manufacturing process specific for Treg cells, which is different from conventional CAR-T processes.”
Quell has developed a GMP manufacturing process to produce CAR-Tregs and has already made supplies of QEL-001 for the ongoing Phase I/II “LIBERATE” study, which is focused on preventing organ rejection in liver transplantation.
Under the partnership, the firms will work together on process transfer and scale-out for several candidates in Quell’s pipeline. Manufacturing will take place at eXmoor’s cell and gene therapy center in Bristol in the U.K.
“The Center has been designed as a flexible and scalable manufacturing hub, with integrated process development and analytical labs, four Grade C GMP clean rooms, and fill/finish capability,” Foley tells GEN. “It can support scaleup, optimization, and manufacture of cell therapies, RNA therapies, and viral vectors, with up to 2 x 200 L bioreactors and multiple autologous cell therapy stations per suite. In addition, the cutting-edge zero-carbon facility relies entirely on solar technology and heat pumps.”
The partnership will also see eXmoor set aside more manufacturing space for Quell, according to Foley, who adds, “This expanded capacity will enable the supply of these products as they transition into clinical development in the next few years.”

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE